ArticleDiscover oncology2026
Spatially resolved FoxP3 positive lymphocyte infiltration within the tumor microenvironment predicts survival in resected pancreatic ductal adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn pancreatic ductal adenocarcinoma (PDAC), immune and stromal components of the tumor microenvironment critically influence disease progression and survival. Although FoxP3 expression has been linked to prognosis, the clinical relevance of its spatial distribution remains unclear. This study aimed to evaluate the prognostic significance of FoxP3-positive lymphocytes in intratumoral (IT), peritumoral (PT), and tumor-associated stromal (T) compartments. MATERIALS AND
methodsNinety-eight patients with PDAC who underwent surgical resection between 2015 and 2021 were retrospectively analyzed. FoxP3 expression was assessed immunohistochemically in IT, PT, and T compartments and categorized as low or high based on H-scores. Associations with clinicopathological variables, overall survival (OS), and disease-free survival (DFS) were analyzed using Kaplan-Meier and Cox proportional hazards models. Subgroup analyses were performed according to recurrence status and receipt of adjuvant chemotherapy.
resultsHigh FoxP3 expression in IT, PT, and T compartments was significantly associated with shorter OS. Although FoxP3 expression showed significant associations with DFS in Kaplan-Meier analyses, it did not retain independent significance in multivariate models. Tumor-associated stromal FoxP3 expression correlated with increased stromal response and advanced nodal stage, whereas high PT-FoxP3 expression was associated with positive surgical margins. In patients receiving adjuvant chemotherapy, Kaplan-Meier analyses showed no clear survival separation; however, compartment-specific prognostic effects of FoxP3 were preserved in multivariate analyses.
conclusionFoxP3-positive lymphocyte infiltration represents a clinically relevant prognostic biomarker in PDAC, with its impact on survival strongly dependent on spatial localization within the tumor microenvironment. Compartment-based evaluation of FoxP3 may improve risk stratification and provide a biologically meaningful framework for future immunologically informed therapeutic strategies in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.